RU2019108824A - Соединения для лечения заболеваний, связанных с дисфункцией митохондрий - Google Patents

Соединения для лечения заболеваний, связанных с дисфункцией митохондрий Download PDF

Info

Publication number
RU2019108824A
RU2019108824A RU2019108824A RU2019108824A RU2019108824A RU 2019108824 A RU2019108824 A RU 2019108824A RU 2019108824 A RU2019108824 A RU 2019108824A RU 2019108824 A RU2019108824 A RU 2019108824A RU 2019108824 A RU2019108824 A RU 2019108824A
Authority
RU
Russia
Prior art keywords
group
carbon atoms
compound
pharmaceutically acceptable
hydrate
Prior art date
Application number
RU2019108824A
Other languages
English (en)
Russian (ru)
Other versions
RU2019108824A3 (cg-RX-API-DMAC7.html
Inventor
Антуан ДАНШЕН
Агнешка СЕКОВСКАЯ
Патрис ГАРНЬЕ
Original Assignee
Амабайотикс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амабайотикс filed Critical Амабайотикс
Publication of RU2019108824A publication Critical patent/RU2019108824A/ru
Publication of RU2019108824A3 publication Critical patent/RU2019108824A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2019108824A 2016-08-30 2017-08-30 Соединения для лечения заболеваний, связанных с дисфункцией митохондрий RU2019108824A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16306094.0 2016-08-30
EP16306094.0A EP3290039B1 (en) 2016-08-30 2016-08-30 Compounds for treating diseases associated with a mitochondrial dysfonction
PCT/EP2017/071812 WO2018041919A1 (en) 2016-08-30 2017-08-30 Compounds for treating diseases associated with a mitochondrial dysfonction

Publications (2)

Publication Number Publication Date
RU2019108824A true RU2019108824A (ru) 2020-10-01
RU2019108824A3 RU2019108824A3 (cg-RX-API-DMAC7.html) 2020-12-31

Family

ID=56896495

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019108824A RU2019108824A (ru) 2016-08-30 2017-08-30 Соединения для лечения заболеваний, связанных с дисфункцией митохондрий

Country Status (15)

Country Link
US (2) US10857135B2 (cg-RX-API-DMAC7.html)
EP (2) EP3290039B1 (cg-RX-API-DMAC7.html)
JP (1) JP7065854B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200011927A (cg-RX-API-DMAC7.html)
CN (1) CN110035758B (cg-RX-API-DMAC7.html)
AU (1) AU2017317651B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019004236A2 (cg-RX-API-DMAC7.html)
CA (1) CA3034694A1 (cg-RX-API-DMAC7.html)
ES (1) ES2800917T3 (cg-RX-API-DMAC7.html)
MA (1) MA46099A (cg-RX-API-DMAC7.html)
MX (1) MX394782B (cg-RX-API-DMAC7.html)
RU (1) RU2019108824A (cg-RX-API-DMAC7.html)
SG (1) SG11201901689YA (cg-RX-API-DMAC7.html)
WO (1) WO2018041919A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201900997B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3290039B1 (en) * 2016-08-30 2020-03-25 Amabiotics Compounds for treating diseases associated with a mitochondrial dysfonction
JP2021517124A (ja) * 2018-03-07 2021-07-15 エーエムエーバイオティクス アルツハイマー病を治療するための化合物
US20220096574A1 (en) * 2019-01-29 2022-03-31 Holobiome, Inc. Methods and compositions for treating and preventing central nervous system disorders and other conditions caused by gut microbial dysbiosis
EP4028014A1 (en) * 2019-09-12 2022-07-20 Stellate Therapeutics Compounds for treating neurodegenerative diseases
WO2021048431A1 (en) * 2019-09-12 2021-03-18 Amabiotics Compounds for treating ataxia
CN116850191A (zh) * 2023-06-16 2023-10-10 山东大学齐鲁医院 奎因在制备治疗线粒体功能障碍相关疾病药物中的应用
WO2026057085A1 (zh) * 2024-09-15 2026-03-19 澳门科技大学 Queuine在抗衰老中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936615A (ja) * 1982-08-24 1984-02-28 Takeda Chem Ind Ltd 発がん予防剤
US6020139A (en) * 1995-04-25 2000-02-01 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
JPH11506426A (ja) * 1995-04-25 1999-06-08 オリディグム コーポレイション 代謝経路のs−アデノシルメチオニン調節ならびに診断および治療におけるその使用
FR3002139B1 (fr) * 2013-02-21 2015-06-19 Amabiotics Utilisation cosmetique de la queuine
GB201417163D0 (en) * 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
GB201417165D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
EP3290039B1 (en) * 2016-08-30 2020-03-25 Amabiotics Compounds for treating diseases associated with a mitochondrial dysfonction

Also Published As

Publication number Publication date
BR112019004236A2 (pt) 2019-05-28
JP2019526634A (ja) 2019-09-19
EP3290039A1 (en) 2018-03-07
AU2017317651B2 (en) 2022-12-15
SG11201901689YA (en) 2019-03-28
US20210046056A1 (en) 2021-02-18
CN110035758A (zh) 2019-07-19
US10857135B2 (en) 2020-12-08
MA46099A (fr) 2019-07-10
MX394782B (es) 2025-03-24
ZA201900997B (en) 2020-05-27
ES2800917T3 (es) 2021-01-05
US11684611B2 (en) 2023-06-27
CA3034694A1 (en) 2018-03-08
MX2019002369A (es) 2019-11-07
JP7065854B2 (ja) 2022-05-12
KR20200011927A (ko) 2020-02-04
EP3506903A1 (en) 2019-07-10
EP3290039B1 (en) 2020-03-25
CN110035758B (zh) 2023-06-16
RU2019108824A3 (cg-RX-API-DMAC7.html) 2020-12-31
WO2018041919A1 (en) 2018-03-08
AU2017317651A1 (en) 2019-03-07
US20190224174A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
JP2019526634A5 (cg-RX-API-DMAC7.html)
EP3581187B1 (en) Skin pigmentation inhibitor
KR950702994A (ko) 탁솔과 복합된, 단백질 키나제 억제제 및 관련 화합물(protein kinase inhibitors and related compounds combined with taxol)
CN113164420B (zh) 治疗组合物
BR112015026410A2 (pt) derivados de dolastatina 10 e auristatinas
CA2909160A1 (en) Formulations of oxabicycloheptanes and oxabicycloheptenes
RU2015148931A (ru) Нутритивная композиция для улучшения функции мозга при фенилкетонурии
US11471429B2 (en) Synthetic capsaicin analogues as bioenhancers
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
JP2024037922A (ja) 急性放射線症候群を予防又は処置するための組成物
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
ES2395401T3 (es) kit para la terapia del cáncer y composición farmacéutica para la terapia del cáncer
CN115335047A (zh) 用于治疗血管脂肪瘤的组合物
RU2020132761A (ru) Соединения для лечения болезни альцгеймера
KR101245328B1 (ko) 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신 및/또는 데커시놀 안젤레이트를 유효성분으로 하는 당귀추출물을 포함하는 항암제 조성물
FI3503899T3 (fi) Tuote ja menetelmä uridiinipitoisuuden lisäämiseksi plasmassa
EP3130337B1 (en) Combination of a urinary basifying agent and an uric acid crystallisation inhibitor for the treatment or prevention of renal lithiasis
CN107848948A (zh) 10‑羟基‑顺‑12‑十八碳烯酸烷基酯及其用途
RU2016115374A (ru) Фармацевтические композиции, содержащие антибактериальные агенты
RU2015111491A (ru) Комбинация макроциклического ингибитора протеазы hcv, ненуклеозидного ингибитора hcv и ритонавира
Corsetti et al. Protect and counter-attack: Nutritional supplementation with essential amino acid ratios reduces doxorubicin–induced cardiotoxicity In Vivo and promote cancer cell death In Vitro
TWI673050B (zh) 外用醫藥組成物
RU2016115376A (ru) Фармацевтические композиции, содержащие антибактериальные агенты
JP2648176B2 (ja) 制癌剤
CZ26004U1 (cs) Potravinový doplněk kompenzující nepříznivé účinky očkování